Table 3.
Comparison of patients with echocardiography and patients with missing examination after 12 months
| Variable | 12 months dropouts [n = 21] | 12 months completers [n = 50] | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean ± standard deviation or n and (%) | 95% CI (mean) | median and interquartile ranges | Mean ± standard deviation or n and % | 95% CI (mean) | median and interquartile ranges | ||||||
| N | lower limit | upper limit | N | lower limit | upper limit | p-value | |||||
| Demographics | |||||||||||
| Age [years] | 21 | 59.5 ± 11.66 | 54.2 | 64.8 | 56 [49; 71] | 50 | 59.0 ± 14.2 | 54.9 | 63.0 | 60 [51; 71] | 0.845 |
| Height [cm] | 21 | 170.1 ± 10.95 | 165.1 | 175.1 | 172 [163; 175] | 50 | 166.5 ± 9.3 | 163.9 | 169.2 | 168 [160; 173] | 0.267 |
| Weight [kg] | 21 | 78.7 ± 12.5 | 73.0 | 84.4 | 75.0 [71; 88] | 50 | 76.2 ± 19.3 | 70.7 | 81.6 | 71 [65; 85] | 0.196 |
| BMI [kg/m2] | 21 | 27.2 ± 3.5 | 25.6 | 28.8 | 26.8 [25.7; 28.4] | 50 | 27.3 ± 5.6 | 25.7 | 28.9 | 26.0 [23.3; 30.0] | 0.575 |
| gender [female n (%)] | 11 (52.4%) | 27 (54.0%) | |||||||||
| Pulmonary hypertension etiology | |||||||||||
| Idiopathic PAH | 3 (14.3%) | 11 (22.0%) | |||||||||
| Other PAH | 6 (28.6%) | 12 (24.0%) | |||||||||
| Chronic thromboembolic pulmonary hypertension | 12 (57.1%) | 27 (54.0%) | |||||||||
| WHO functional class | |||||||||||
| II | 6 (28.6%) | 11 (22.0%) | |||||||||
| III | 15 (71.4%) | 39 (78.0%) | |||||||||
| Pulmonary hypertension targeted treatment | |||||||||||
| treatment naÏve | 2 (33.3%) | 35 (70%) | |||||||||
| Endothelin-Receptor-Antagonist | 2 (33.3%) | 12 (24%) | |||||||||
| Phosphodiesterase-5-inhibitor | 2 (33.3%) | 3 (6%) | |||||||||
| Oxygen | 2 (33.3%) | 5 (10%) | |||||||||
| Vital signs | |||||||||||
| Systolic Blood Pressure [mmHg] | 21 | 116 ± 12 | 110 | 121 | 110 [110; 125] | 50 | 114 ± 14 | 110 | 121 | 110 [110; 125] | 0.378 |
| Diastolic Blood Pressure [mmHg] | 21 | 75 ± 10 | 71 | 80 | 76 [70; 80] | 50 | 71 ± 10 | 68 | 73 | 70 [64; 80] | 0.040 |
| Heart Rate [bpm] | 21 | 79 ± 9 | 75 | 83 | 80 [72; 84] | 50 | 81 ± 11 | 78 | 84 | 80 [73; 88] | 0.645 |
| Clinical parameters | |||||||||||
| NTproBNP [pmol/L] | 11 | 183.7 ± 243.4 | 20.2 | 347.2 | 76 [29.6; 217.4] | 30 | 125.3 ± 228.4 | 40.0 | 210.6 | 42.2 [17.4; 144.8] | 0.471 |
| 6-min walking distance [meters] | 18 | 338.5 ± 99.9 | 288.8 | 388.2 | 362 [270; 406] | 50 | 366.4 ± 88.1 | 341.3 | 391.4 | 370 [301; 420] | 0.440 |
| Hemodynamics measured by right heart catheter | |||||||||||
| mean PAP [mmHg] | 13 | 48.6 ± 54.1 | 43.0 | 54.1 | 47 [45; 57] | 32 | 45.1 ± 10.1 | 41.5 | 48.8 | 43.5 [37.8; 53.3] | 0.215 |
| Pulmonary Vascular Resistance [dyn*sec*cm− 5] | 13 | 781.3 ± 259.3 | 624.6 | 938.0 | 747.8 [615.4; 904.3] | 32 | 668.0 ± 289.3 | 563.8 | 772.3 | 563.1 [495.2; 789.7] | 0.112 |
| Cardiac Index [L/min/m2] | 13 | 2.4 ± 0.5 | 2.1 | 2.7 | 2.5 [2.2; 2.7] | 32 | 2.6 ± 0.5 | 2.4 | 2.7 | 2.6 [2.4; 2.8] | 0.276 |
| Cardiac Output [L/min] | 13 | 4.6 ± 0.9 | 4.0 | 5.1 | 4.6 [4.3; 5.2] | 32 | 4.8 ± 1.1 | 4.3 | 5.2 | 4.6 [4.3; 8.2] | 0.861 |
| Pulmonary Arterial Wedge Pressure [mmHg] | 13 | 6.0 ± 2.7 | 4.4 | 7.6 | 6 [5; 8] | 32 | 7.9 ± 2.8 | 6.9 | 8.9 | 7 [6; 10] | 0.052 |
CI confidence interval, BMI Body mass index, NTproBNP N-terminal fragment of pro brain natriuretic peptide, PAP pulmonary arterial pressure